Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daniel O'Day
Biotech
Gilead's O'Day relishes reunion as Berger agrees to leave Sanofi
Dietmar Berger's appointment reunites Gilead CEO Daniel O’Day with a key member of the oncology team from his time at Roche.
Nick Paul Taylor
Dec 13, 2024 5:20am
CymaBay board pushed for 50 cent top up to Gilead's $32.50 offer
Feb 26, 2024 10:49am
Gilead hits go on a host of Arcus cancer programs
Nov 18, 2021 8:00am
Gilead poaches Amgen exec Flavius Martin to run its R&D
Mar 26, 2021 9:40am
Gilead nabs $300M option to buy cancer I-O biotech Tizona
Jul 21, 2020 9:20am
Gilead CEO: Remdesivir could become benchmark for COVID-19 R&D
Apr 30, 2020 7:13pm
